Comparison of the analytical and clinical performances of Abbott RealTime High Risk HPV, Hybrid Capture 2, and DNA Chip assays in gynecology patients

Diagnostic Microbiology and Infectious Disease

Volumn 76, Issue 4, 2013, Pages 432-436

  Park, Seungman ^a,b   Kang, Youjin ^a   Kim, Dong Geun ^a   Kim, Eui Chong ^a   Park, Sung Sup ^a   Seong, Moon Woo ^a  

^a Seoul National University Hospital   (South Korea)

^b Konkuk University Hospital   (South Korea)

Author keywords

Chip; HC2; HPV; Performance; Real time PCR

Indexed keywords

VIRUS DNA;

ADULT; AGED; ARTICLE; CANCER GRADING; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DNA MICROARRAY; FEMALE; GENOTYPE; HISTOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; SQUAMOUS EPITHELIUM; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; WART VIRUS;

CHIP; HC2; HPV; PERFORMANCE; REAL-TIME PCR;

ADULT; AGED; AGED, 80 AND OVER; CERVIX UTERI; EARLY DETECTION OF CANCER; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; MIDDLE AGED; MOLECULAR TYPING; NEOPLASM GRADING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PREGNANCY; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS;

EID: 84880753700     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2013.04.012     Document Type: Article

References (38)

1. Arbyn M., Van Oyen H., Lynge E., Micksche M., Faivre J., Jordan J. European Commission's proposal for a council recommendation on cancer screening. BMJ 2003, 327(7409):289-290.
2. Baay M.F., Quint W.G., Koudstaal J., Hollema H., Duk J.M., Burger M.P., et al. Comprehensive study of several general and type-specific primer pairs for detection of human papillomavirus DNA by PCR in paraffin-embedded cervical carcinomas. J Clin Microbiol 1996, 34(3):745-747.
3. Baldwin P., Laskey R., Coleman N. Translational approaches to improving cervical screening. Nat Rev Cancer 2003, 3(3):217-226.
4. Baseman J.G., Koutsky L.A. The epidemiology of human papillomavirus infections. J Clin Virol 2005, 32(Suppl 1):S16-S24.
5. Carozzi F.M., Burroni E., Bisanzi S., Puliti D., Confortini M., Giorgi Rossi P., et al. Comparison of clinical performance of Abbott RealTime High Risk HPV test with that of hybrid capture 2 assay in a screening setting. J Clin Microbiol 2011, 49(4):1446-1451.
6. Castellsague X. Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol 2008, 110(3 Suppl 2):S4-S7.
7. Chan S.Y., Delius H., Halpern A.L., Bernard H.U. Analysis of genomic sequences of 95 papillomavirus types: uniting typing, phylogeny, and taxonomy. J Virol 1995, 69(5):3074-3083.
8. Cho N.H., An H.J., Jeong J.K., Kang S., Kim J.W., Kim Y.T., et al. Genotyping of 22 human papillomavirus types by DNA chip in Korean women: comparison with cytologic diagnosis. Am J Obstet Gynecol 2003, 188(1):56-62.
9. Choi Y.D., Jung W.W., Nam J.H., Choi H.S., Park C.S. Detection of HPV genotypes in cervical lesions by the HPV DNA Chip and sequencing. Gynecol Oncol 2005, 98(3):369-375.
10. Cuschieri K.S., Cubie H.A., Whitley M.W., Gilkison G., Arends M.J., Graham C., et al. Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study. J Clin Pathol 2005, 58(9):946-950.
11. de Roda Husman A.M., Walboomers J.M., van den Brule A.J., Meijer C.J., Snijders P.J. The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 1995, 76(Pt 4):1057-1062.
12. Gravitt P.E., Peyton C.L., Alessi T.Q., Wheeler C.M., Coutlee F., Hildesheim A., et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000, 38(1):357-361.
13. Halfon P., Benmoura D., Agostini A., Khiri H., Penaranda G., Martineau A., et al. Evaluation of the clinical performance of the Abbott RealTime High-Risk HPV for carcinogenic HPV detection. J Clin Virol 2010, 48(4):246-250.
14. Hsing A.W., Burk R.D., Liaw K.L., Chen C.J., Zhang T., Schiffman M., et al. Interlaboratory agreement in a polymerase chain reaction-based human papillomavirus DNA assay. Cancer Epidemiol Biomarkers Prev 1996, 5(6):483-484.
15. Huang S., Tang N., Mak W.B., Erickson B., Salituro J., Li Y., et al. Principles and analytical performance of Abbott RealTime High Risk HPV test. J Clin Virol 2009, 45(Suppl 1):S13-S17.
16. Huang S., Erickson B., Tang N., Mak W.B., Salituro J., Robinson J., et al. Clinical performance of Abbott RealTime High Risk HPV test for detection of high-grade cervical intraepithelial neoplasia in women with abnormal cytology. J Clin Virol 2009, 45(Suppl 1):S19-S23.
17. Hwang Y., Lee M. Comparison of the AdvanSure human papillomavirus screening real-time PCR, the Abbott RealTime High Risk human papillomavirus test, and the Hybrid Capture human papillomavirus DNA test for the detection of human papillomavirus. Ann Lab Med 2012, 32(3):201-205.
18. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
19. Karlsen F., Kalantari M., Jenkins A., Pettersen E., Kristensen G., Holm R., et al. Use of multiple PCR primer sets for optimal detection of human papillomavirus. J Clin Microbiol 1996, 34(9):2095-2100.
20. Lee E.H., Chung H.J., Oh H.B., Chi H.S., Jee M.S., Park S.N., et al. Human papilloma virus genotyping assay using restriction fragment mass polymorphism analysis, and its comparison with sequencing and hybrid capture assays. Korean J Lab Med 2007, 27(1):62-68.
21. Lorincz A.T. Hybrid Capture method for detection of human papillomavirus DNA in clinical specimens: a tool for clinical management of equivocal Pap smears and for population screening. J Obstet Gynaecol Res 1996, 22(6):629-636.
22. Michalas S.P. The Pap test: George N. Papanicolaou (1883-1962). A screening test for the prevention of cancer of uterine cervix. Eur J Obstet Gynecol Reprod Biol 2000, 90(2):135-138.
23. Munoz N. Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol 2000, 19(1-2):1-5.
24. Oh T.J., Kim C.J., Woo S.K., Kim T.S., Jeong D.J., Kim M.S., et al. Development and clinical evaluation of a highly sensitive DNA microarray for detection and genotyping of human papillomaviruses. J Clin Microbiol 2004, 42(7):3272-3280.
25. Park Y., Lee E., Choi J., Jeong S., Kim H.S. Comparison of the Abbott RealTime High-Risk Human Papillomavirus (HPV), Roche Cobas HPV, and Hybrid Capture 2 assays to direct Sequencing and genotyping of HPV DNA. J Clin Microbiol 2012, 50(7):2359-2365.
26. Poljak M., Brencic A., Seme K., Vince A., Marin I.J. Comparative evaluation of first- and second-generation digene hybrid capture assays for detection of human papillomaviruses associated with high or intermediate risk for cervical cancer. J Clin Microbiol 1999, 37(3):796-797.
27. Poljak M., Kovanda A., Kocjan B.J., Seme K., Jancar N., Vrtacnik-Bokal E. The Abbott RealTime High Risk HPV test: comparative evaluation of analytical specificity and clinical sensitivity for cervical carcinoma and CIN 3 lesions with the Hybrid Capture 2 HPV DNA test. Acta Dermatovenerol Alp Panonica Adriat 2009, 18(3):94-103.
28. Poljak M., Ostrbenk A., Seme K., Ucakar V., Hillemanns P., Bokal E.V., et al. Comparison of clinical and analytical performance of the Abbott Realtime High Risk HPV test to the performance of hybrid capture 2 in population-based cervical cancer screening. J Clin Microbiol 2011, 49(5):1721-1729.
29. Qu W., Jiang G., Cruz Y., Chang C.J., Ho G.Y., Klein R.S., et al. PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems. J Clin Microbiol 1997, 35(6):1304-1310.
30. Schiffman M.H., Bauer H.M., Lorincz A.T., Manos M.M., Byrne J.C., Glass A.G., et al. Comparison of Southern blot hybridization and polymerase chain reaction methods for the detection of human papillomavirus DNA. J Clin Microbiol 1991, 29(3):573-577.
31. Smits H.L., Bollen L.J., Tjong A.H.S.P., Vonk J., Van Der Velden J., Ten Kate F.J., et al. Intermethod variation in detection of human papillomavirus DNA in cervical smears. J Clin Microbiol 1995, 33(10):2631-2636.
32. Stoler M.H. HPV testing in cervical cytology practice: it's all about choice. Acta Cytol 2005, 49(2):117-119.
33. Stoler M.H.C.P., Solomon D., Schiffman M. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol 2007, 127(3):335-337.
34. Syrjanen S., Partanen P., Mantyjarvi R., Syrjanen K. Sensitivity of in situ hybridization techniques using biotin- and 35S-labeled human papillomavirus (HPV) DNA probes. J Virol Methods 1988, 19(3-4):225-238.
35. Szarewski A., Mesher D., Cadman L., Austin J., Ashdown-Barr L., Ho L., et al. Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the predictors 2 study. J Clin Microbiol 2012, 50(6):1867-1873.
36. Woodman C.B., Collins S.I., Young L.S. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 2007, 7(1):11-22.
37. Wright T.C. Cervical cancer screening in the 21st century: is it time to retire the PAP smear?. Clin Obstet Gynecol 2007, 50(2):313-323.
38. zur Hausen H. Condylomata acuminata and human genital cancer. Cancer Res 1976, 36(2 pt 2):794.